2025-03-10 21:02:03
Latest Post
Syngene acquires its First Manufacturing Facility in the US 
Thermax Partners with Brazil-Based OCQ for High-Performance Chemicals
BEL receives orders worth Rs.843 Crore
RVNL signed MoU with M/s Abhinava Strategic Partners Pvt Ltd
Gensol Engineering promoter demonstrates unwavering commitment with INR 29 Cr. Equity Infusion
Stock Report
Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
Posted On : 2024-07-29 22:31:14( TIMEZONE : IST )
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's"), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the launch of its proposed biosimilar Rituximab candidate DRL_RI (ITUXREDI®) in European markets.
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance and drug product manufacturing facility located in Hyderabad, India. As part of the established approval process, the CHMP positive opinion will now be reviewed by the European Commission (EC), following which a decision will be made on the grant of marketing authorisation in the European Union (EU) member countries, and the European Economic Area (EEA) member states of Norway, Iceland, and Liechtenstein. A Marketing Authorisation Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA) will be made separately in keeping with the reliance route under the International Recognition Procedure (IRP).
DRL_RI is being developed as a biosimilar of MabThera® (Rituximab), a cluster of differentiation 20 (CD20) directed cytolytic antibody. ITUXREDI® / DRL_RI (rituximab) is a proposed biosimilar to reference medicinal product MabThera® and the intended indications are the same as those currently approved for MabThera®: Non-Hodgkin's Lymphoma (NHL); Chronic Lymphocytic Leukaemia (CLL); Rheumatoid Arthritis (RA); Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA); Pemphigus Vulgaris (PV).
EMA reference product, MabThera®, is a registered trademark of Roche.
Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 6840.05 as compared to the previous close of Rs. 6892.15. The total number of shares traded during the day was 18697 in over 5194 trades.
The stock hit an intraday high of Rs. 7030.00 and intraday low of 6740.00. The net turnover during the day was Rs. 127784050.00.
